McKesson Corporation Q3 2026 Earnings Recap

MCK Q3 2026 February 5, 2026

Get alerts when MCK reports next quarter

McKesson Corporation delivered robust third-quarter results for fiscal 2026, showcasing double-digit revenue and earnings growth driven by continued strength in oncology, biopharma services, and North American distribution. The company raised its full-year EPS guidance, reflecting strong momentum across its strategic initiatives.

Earnings Per Share Beat

$9.34 vs $9.17 est.

+1.9% surprise

Revenue Beat

106158000000 vs 105795200000 est.

+0.3% surprise

Market Reaction

1-Day -0.95%

5-Day -4.36%

30-Day -3.04%

See MCK alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue and adjusted EPS increased by 17-19% year-over-year, indicating strong business momentum.
Integration of acquired entities such as Florida Cancer Specialists and Prism Vision enhances McKesson's oncology services and market position.
Introduction of 50 new programs across diverse brands demonstrates strong demand for patient access and affordability solutions.
Continued investment in technology improves workflow efficiency, with employees now supporting 120 more patients per full-time staff in annual verification.
Strong partnerships with manufacturers and advocacy efforts align with the evolving healthcare landscape and regulatory changes.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MCK on AllInvestView.

Next Q4 2026